Kaboom is correct if the data shines in a powered placebo controlled Phase 2B against a blockbuster only approved oral in the world expected to achieve $2.6B in revenue in 2018. Kaboom would be correct. Keep in mind that Otezla has sluggish uptake and low efficacy and many side effects. Kaboom.
News 
Market Data 
Discover 
